Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial

Background: Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety and efficacy of dalfampridine-ER 5 mg compared with 10 mg. Methods: Patients were randomized to double-blind treatment with twice-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J MS Care
Main Authors: Yapundich, Robert, Applebee, Angela, Bethoux, Francois, Goldman, Myla D., Hutton, George J., Mass, Michele, Pardo, Gabriel, Klingler, Michael, Henney, Herbert R., Blight, Andrew R., Carrazana, Enrique J.
Formato: Artigo
Idioma:Inglês
Publicado em: The Consortium of Multiple Sclerosis Centers 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4455866/
https://ncbi.nlm.nih.gov/pubmed/26052259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2014-040
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados